Behind each blockbuster is a story 12 to 15 years in the making. Three of the blockbuster drugs are for rare and orphan diseases. Until recently, the monies raised selling the drug to a small patient population did not cover the development costs and these drugs were rarely developed. This has changed in recent years as now almost a third of drugs currently on the market for rare diseases now generate more than $1B in sales annually.
This talk will focus on: